Specialists of the Russian nuclear industry have begun preclinical trials of a radiopharmaceutical drug for the "targeted" destruction of prostate cancer. The scale of the spread of oncological diseases requires the use of new radioactive isotopes for their treatment. Such isotopes are recognized as so-called alpha emitters, which effectively kill cancer cells and significantly increase the survival rate of patients compared to traditional chemotherapy.

Scientists have started preclinical studies of a targeted radiopharmaceutical based on thorium-227 isotope and antibodies intended for the treatment of prostate cancer. The research will be carried out by specialists of the "Isotope" all-regional association, part of Rosatom, on the basis of the Kapitsa Research Institute of Technology of Ulyanovsk State University named after    Sergey Kapitsa. Work on the project is scheduled until the middle of next year. It is implemented in cooperation with the leading scientific centers of Russia – the Russian Scientific Center of Radiology and Surgical Technologies named after Academician Granov (St. Petersburg), the Research Institute of Atomic Reactors (Dimitrovgrad), the Institute of Organoelement Compounds of the Russian Academy of Sciences and the innovative private company Innova Plus, which conducts molecular biological research.